GlassScriptPhysician profile
Barbara Anne Etheridge
NPI 1184792814
$3,064.95
in general payments reported to CMS, 2019-2025
25 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $897 · 2020: $833 · 2021: $739 · 2022: $261 · 2023: $57.45 · 2024: $94.81 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $335.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $776.45 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $719.51 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $331.41 | 2019-2023 | Mounjaro |
| Pfizer INC. | $280.89 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $141.48 | 2019-2021 | |
| Abbvie INC. | $135.56 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.62 | 2019-2025 | Jardiance |
| Exact Sciences Corporation | $66.98 | 2025 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $66.74 | 2019-2021 | |
| Amarin Pharma, INC. | $55.24 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.45 | 2022-2024 | |
| Abbott Laboratories | $41.22 | 2021 | |
| Vanda Pharmaceuticals INC. | $40.20 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.54 | 2019-2021 | |
| Eisai INC. | $38.24 | 2019 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $30.66 | 2019 | |
| Janssen Pharmaceuticals, INC | $27.62 | 2019 | |
| Novartis Pharmaceuticals Corporation | $26.51 | 2019-2020 | |
| Ibsa Pharma INC. | $23.79 | 2019-2020 | |
| Bausch Health US, LLC | $16.96 | 2022 | |
| Celgene Corporation | $14.76 | 2019 | |
| Daiichi Sankyo INC. | $14.54 | 2021 | |
| Esperion Therapeutics, INC. | $13.69 | 2021 | |
| Nalpropion Pharmaceuticals LLC | $13.64 | 2019 | |
| Scilex Pharmaceuticals INC. | $13.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Barbara Etheridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.